Safety and Efficacy of Ramelteon in Adults With Chronic Insomnia

This study has been completed.

Study NCT00671125 Information provided by Takeda Global Research & Development Center, Inc.

First Received: May 1, 2008 Last Updated: May 4, 2010 History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Study Status:	This study has been completed.
Study Completion Date:	September 2003
Primary Completion Date:	September 2003 (Final data collection date for primary outcome measure)

Publications:

Zammit G, Erman M, Wang-Weigand S, Sainati S, Zhang J, Roth T. Evaluation of the efficacy and safety of ramelteon in subjects with chronic insomnia. J Clin Sleep Med. 2007 Aug 15;3(5):495-504. Erratum in: J Clin Sleep Med. 2007 Oct 15;3(6):table of contents. J Clin Sleep Med. 2008 Oct 15;4(5):table of contents.

Mini L, Wang-Weigand S, Zhang J. Ramelteon 8 mg/d Versus Placebo in Patients with Chronic Insomnia: Post Hoc Analysis of a Five-Week Trial Using 50% or Greater Reduction in Latency to Persistent Sleep as a Measure of Treatment Effect. Clin Ther 2008;30:(7):1316-1323

Osborne, T, Louis, M, Wang-Weigand, S and Jie, Z. Treatment of insomnia in women and the melatonin receptor agonist ramelteon (Rozerem). Women's Health Care: A Practical Journal for Nurse Practitioners. 2008; 7: (6): 24-30

Wang-Weigand S, McCue M, Ogrinc F, Mini L. Effects of ramelteon 8 mg on objective sleep latency in adults with chronic insomnia on nights 1 and 2: pooled analysis. Curr Med Res Opin. 2009 May;25(5):1209-13.